Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2022-01-27 00:00:00 ET · period of report 2022-01-25 · accession 0001209191-22-005202 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-27 | 2022-01-25 | PCRX | STACK DAVID M | CEO, COB, Dir | M - OptEx | $10.81 | +13.7K | 123.0K | +12% | +$147.8K |
| D | 2022-01-27 | 2022-01-25 | PCRX | STACK DAVID M | CEO, COB, Dir | M - OptEx | $0.00 | -13.7K | 45.0K | -23% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-25 | M | A | 13,670 | $10.81 | 123,044 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-25 | M | D | 13,670 | $0.00 | 45,000 | D | $10.81 · — to 2022-06-05 | 13,670 Common Stock | (F2) The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months. |